Notice: This company has been marked as potentially delisted and may not be actively trading. GTX (GTXI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends GTXI vs. RGLS, AGEN, FBIO, SABS, CRIS, BOLT, MTEM, AMGN, VRTX, and GILDShould you be buying GTX stock or one of its competitors? The main competitors of GTX include Regulus Therapeutics (RGLS), Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry. GTX vs. Regulus Therapeutics Agenus Fortress Biotech SAB Biotherapeutics Curis Bolt Biotherapeutics Molecular Templates Amgen Vertex Pharmaceuticals Gilead Sciences GTX (NASDAQ:GTXI) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking. Is GTXI or RGLS more profitable? Regulus Therapeutics' return on equity of -53.07% beat GTX's return on equity.Company Net Margins Return on Equity Return on Assets GTXN/A -104.19% -86.42% Regulus Therapeutics N/A -53.07%-48.58% Does the media refer more to GTXI or RGLS? In the previous week, Regulus Therapeutics had 2 more articles in the media than GTX. MarketBeat recorded 5 mentions for Regulus Therapeutics and 3 mentions for GTX. GTX's average media sentiment score of 0.00 beat Regulus Therapeutics' score of -0.30 indicating that GTX is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GTX 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regulus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer GTXI or RGLS? Regulus Therapeutics received 175 more outperform votes than GTX when rated by MarketBeat users. However, 73.60% of users gave GTX an outperform vote while only 63.80% of users gave Regulus Therapeutics an outperform vote. CompanyUnderperformOutperformGTXOutperform Votes31573.60% Underperform Votes11326.40% Regulus TherapeuticsOutperform Votes49063.80% Underperform Votes27836.20% Which has higher valuation & earnings, GTXI or RGLS? Regulus Therapeutics is trading at a lower price-to-earnings ratio than GTX, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGTXN/AN/A-$38.42M-$1.65-0.69Regulus TherapeuticsN/AN/A-$30.04M-$1.07-1.31 Do analysts prefer GTXI or RGLS? Regulus Therapeutics has a consensus target price of $10.80, indicating a potential upside of 671.43%. Given Regulus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Regulus Therapeutics is more favorable than GTX.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GTX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Regulus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more risk and volatility, GTXI or RGLS? GTX has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Do insiders and institutionals hold more shares of GTXI or RGLS? 9.5% of GTX shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 40.9% of GTX shares are owned by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryRegulus Therapeutics beats GTX on 10 of the 15 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get GTX News Delivered to You Automatically Sign up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTXI vs. The Competition Export to ExcelMetricGTXPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.42M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-0.695.5095.1214.22Price / SalesN/A375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book1.0510.276.976.37Net Income-$38.42M$153.22M$118.73M$225.56M GTX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTXIGTXN/A$1.14+5.6%N/A+248.2%$27.42MN/A-0.6921RGLSRegulus Therapeutics2.4696 of 5 stars$1.40flat$10.80+671.4%+0.0%$91.70MN/A-1.3130AGENAgenus3.8896 of 5 stars$2.84+6.4%$10.00+252.1%-82.0%$66.63M$156.31M-0.25389Analyst RevisionGap UpFBIOFortress Biotech3.0653 of 5 stars$1.58+0.3%$13.67+767.7%-43.9%$43.47M$84.51M0.00186Analyst ForecastAnalyst RevisionGap UpSABSSAB Biotherapeutics3.5393 of 5 stars$2.95-3.6%$12.40+320.3%+267.0%$27.23M$2.24M0.00140Gap UpCRISCuris2.0271 of 5 stars$4.01+8.4%$23.00+473.6%-56.3%$23.98M$10.02M-0.5149BOLTBolt Biotherapeutics3.4321 of 5 stars$0.57+0.2%$3.50+513.0%-37.7%$21.85M$7.88M0.00100MTEMMolecular Templates2.2513 of 5 stars$0.37-4.6%N/A-92.0%$2.44M$57.31M0.0062Insider TradeGap UpAMGNAmgen4.9108 of 5 stars$289.65+0.6%$333.57+15.2%+8.5%$155.70B$28.19B36.8626,700Ex-DividendShort Interest ↓Positive NewsVRTXVertex Pharmaceuticals4.0563 of 5 stars$449.25-0.4%$499.12+11.1%+26.5%$115.70B$9.87B0.005,400Analyst DowngradeNews CoveragePositive NewsGILDGilead Sciences4.658 of 5 stars$89.62+1.1%$94.45+5.4%+16.6%$111.69B$27.12B984.7818,000Analyst UpgradePositive News Related Companies and Tools Related Companies Regulus Therapeutics Competitors Agenus Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Curis Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Vertex Pharmaceuticals Competitors Gilead Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GTXI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GTx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GTX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTXI Stock Alerts